**
In a troubling revelation, internal records have surfaced detailing a meeting between top officials from the Trump administration’s Environmental Protection Agency (EPA) and Bayer CEO Bill Anderson. This encounter, held on 17 June 2025, focused on strategic litigation concerning glyphosate, the active ingredient in Bayer’s widely used herbicide, Roundup. The discussions come amid ongoing legal battles as thousands of individuals claim that glyphosate exposure has led to cancer diagnoses, raising critical concerns about the intersection of corporate interests and public health.
High-Level Meetings and Legal Strategies
The meeting was attended by key figures from the EPA, including Lee Zeldin, the agency’s administrator, and other senior officials. The agenda, as outlined in an internal email, indicated that Bayer’s team intended to discuss “legal/judicial issues,” specifically referencing potential “supreme court action.” This meeting took place just days before the Supreme Court requested input from the Trump administration’s Justice Department regarding Bayer’s ongoing litigation.
Bayer has been embroiled in legal disputes with thousands of plaintiffs who allege that the company neglected to warn consumers about the cancer risks associated with glyphosate. Central to Bayer’s defence is the argument that if the EPA does not mandate a cancer warning for glyphosate products, the company should not be held liable for failing to inform users of these risks. While some courts have sided with Bayer, others have dismissed this preemption argument, which has also faced opposition from the Biden administration’s solicitor general.
In a statement, Bayer downplayed the significance of the meeting, characterising it as a routine component of the regulatory process. However, critics argue that such meetings illustrate a concerning trend where corporate interests supersede public health considerations.
Administration Support for Bayer
Since the June meeting, the Trump administration has taken several actions that have bolstered Bayer’s position in court. In a filing dated 1 December 2025, Solicitor General D. John Sauer urged the Supreme Court to hear Bayer’s case, a request that was subsequently granted, with arguments scheduled for 27 April 2026. Additionally, the White House invoked the Defense Production Act on 18 February 2026 to ensure the continued production of glyphosate herbicides and shield Bayer from potential liabilities.
On 2 March 2026, Sauer submitted an amicus brief to the Supreme Court, representing the full backing of the US government for Bayer’s position. This close alignment raises concerns about the extent to which regulatory bodies prioritise corporate interests over the health and safety of the public.
Voices of Concern
Environmental advocates and legal experts have expressed alarm over the implications of these meetings and subsequent actions. Nathan Donley, the environmental health science director for the Center for Biological Diversity, highlighted the disproportionate influence corporations wield in shaping regulatory outcomes. “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans,” he remarked.
Legal expert Whitney Di Bona echoed these sentiments, questioning whether the EPA has provided the same opportunity for dialogue to those affected by glyphosate. “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability,” she stated, underscoring a troubling imbalance in access to regulatory discussions.
The Broader Context of Regulatory Capture
The implications of this meeting extend beyond Bayer and glyphosate, highlighting a broader pattern of regulatory capture where industry leaders gain preferential access to decision-makers. Naomi Oreskes, a Harvard professor who studies corporate influence in regulation, noted that such interactions suggest a concerning trend in which corporate interests are prioritised over public welfare.
Activists like Zen Honeycutt, founder of Moms Across America, have long been critical of the undue influence that chemical companies exert on regulatory agencies. “Coercion by chemical companies on our regulatory agencies is nothing new,” she stated, emphasising the need for greater accountability and transparency in the regulatory process.
Why it Matters
The revelations surrounding Bayer’s meeting with the EPA underscore a critical challenge in the United States: the pervasive influence of corporate interests on environmental policy and public health. As legal battles continue to unfold over glyphosate, these high-level discussions reveal an alarming trend where the interests of multinational corporations can overshadow the voices of countless individuals advocating for their health and safety. The implications are profound, as they raise fundamental questions about the integrity of regulatory agencies and their commitment to protecting the American public. In an era where environmental justice is paramount, this situation serves as a stark reminder of the need for vigilance and advocacy in the face of corporate power.
